225 related articles for article (PubMed ID: 18693628)
1. [Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Bar-Yosef Y; Mabjeesh NJ; Laufer M; Neulander EZ; Kaver I; Matzkin H
Harefuah; 2008 Jun; 147(6):514-9, 574. PubMed ID: 18693628
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
3. Medical therapy for benign prostatic hyperplasia: a review of the literature.
Clifford GM; Farmer RD
Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
[TBL] [Abstract][Full Text] [Related]
5. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Guay DR
Am J Geriatr Pharmacother; 2004 Mar; 2(1):14-23. PubMed ID: 15555475
[TBL] [Abstract][Full Text] [Related]
6. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
[TBL] [Abstract][Full Text] [Related]
8. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
10. Terazosin for benign prostatic hyperplasia.
Wilt TJ; Howe RW; Rutks IR; MacDonald R
Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
Dutkiewics S
Int Urol Nephrol; 2001; 32(3):423-32. PubMed ID: 11583366
[TBL] [Abstract][Full Text] [Related]
12. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
13. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Chapple CR
Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
[TBL] [Abstract][Full Text] [Related]
14. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
Chapple CR
Br J Urol; 1998 Mar; 81 Suppl 1():34-47; discussion 64-6. PubMed ID: 9589016
[No Abstract] [Full Text] [Related]
16. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia.
Wilde MI; McTavish D
Drugs; 1996 Dec; 52(6):883-98. PubMed ID: 8957159
[TBL] [Abstract][Full Text] [Related]
17. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Fourcade RO
Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
[TBL] [Abstract][Full Text] [Related]
18. [Comparative evaluation of the efficacy of using terazosin and tamsulosin in patients with benign prostatic hyperplasia].
Lopatkin NA; Sivkov AV; Surikov VN; Egorov AA
Urologiia; 2002; (5 Suppl):3-12. PubMed ID: 12518668
[TBL] [Abstract][Full Text] [Related]
19. Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Simmering JE; Welsh MJ; Liu L; Narayanan NS; Pottegård A
JAMA Neurol; 2021 Apr; 78(4):407-413. PubMed ID: 33523098
[TBL] [Abstract][Full Text] [Related]
20. [Alpha blockers in the treatment of benign hyperplasia of the prostate].
Gómez Sancha F; Fernández Arjona M; Peinado Ibarra F; Fernández Borrell A; Mínguez Martínez R; Pereira Sanz I
Rev Clin Esp; 1997 May; 197(5):358-62. PubMed ID: 9280971
[No Abstract] [Full Text] [Related]
[Next] [New Search]
